摘要
目的:比较齐拉西酮胶囊和阿立哌唑治疗精神分裂症的疗效和安全性。方法:将80例符合ICD-10的精神分裂症患者随机分为两组,分别给予齐拉西酮和阿立哌唑治疗8周。于治疗前和治疗后2、4、6、8周末采用阳性症状与阴性症状量表(PANSS)评定临床疗效,副反应症状量表(TESS)评定不良反应。结果:治疗8周后两组疗效近似(P>0.05),两组有效率差异无显著性(P>0.05);阿立哌唑组的副反应发生率高于齐拉西酮组,但差异无显著性(P>0.05)。两药引起的副反应一般为轻度或中度,患者耐受性较好。结论:齐拉西酮和阿立哌唑治疗精神分裂症均有较好疗效,疗效相当,不良反应较小。
Objective： To compare efficacy and safety of Aripiprazole and Ziprasidone in the treatment of schizophrenia. Methods： 80 patients with schizophrenia by ICD - 10 were randomly allocated to two groups treated with Aripiprazole or Ziprasidone for 8 weeks. The Positive and Negative Syndrom Scale （PANSS） and Treatment Emergent Symptoms Scale （TESS） were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,6,8 weeks of treatment.Results： The total effective rates for the Aripiprazole and Ziprasidone groups were similar after 8 weeks（P 〉 0.05）. There was no significant difference between the two groups （ P 〉 0,05）. Incidence of adverse effects in the Aripiprazole group was lower than that in the Ziprasidone group, but the difference was not Significant （ P 〉 0.05）. Their side effects were not serious, and patients often had good torlerability for them. Conclusion： The results suggest that Aripiprazole is as effective as Ziprasidone for the treatment of schizophrenia, and two agents have low side effects profile.
出处
《中国民康医学》
2008年第22期2644-2645,2671,共3页
Medical Journal of Chinese People’s Health
